SION Sionna Therapeutics, Inc.

Nasdaq www.sionnatx.com


$ 39.51 $ 0.70 (1.8 %)    

Thursday, 23-Oct-2025 15:59:53 EDT
QQQ $ 613.86 $ 0.00 (0 %)
DIA $ 468.21 $ 0.00 (0 %)
SPY $ 674.07 $ 0.00 (0 %)
TLT $ 91.34 $ 0.00 (0 %)
GLD $ 373.58 $ 0.00 (0 %)
$ 39.6
$ 38.85
$ 39.50 x 13
$ 46.58 x 30
-- - --
$ 7.26 - $ 43.20
193,535
na
1.75B
$ 0.34
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosisTopline data expected in mid-2026WAL...

Core News & Articles

Freedom Capital Markets analyst Ilya Zubkov initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a Buy rating and an...

Core News & Articles

Jones Trading analyst Debanjana Chatterjee initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a Buy rating and ann...

Core News & Articles

Raymond James analyst Chris Raymond initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a Strong Buy rating and ann...

Core News & Articles

RBC Capital analyst Brian Abrahams initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a Sector Perform rating and ...

Core News & Articles

Sionna Therapeutics (NASDAQ:SION) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $...

Core News & Articles

Data featured in oral presentation and poster session at 48th European Cystic Fibrosis ConferenceWALTHAM, Mass., June 06, 2025 ...

 newly-listed-sionna-therapeutics-touts-positive-data-from-lung-disease-candidate-in-healthy-volunteer-trial

Sionna's CF drug candidates SION-719 and SION-451 showed strong safety and PK results in Phase 1 trials, advancing to mid-s...

Core News & Articles

SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential...

Core News & Articles

Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current t...

Core News & Articles

Sionna Therapeutics (NASDAQ:SION) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of...

Core News & Articles

Stifel analyst Paul Matteis initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a Buy rating and announces Price Ta...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION